Market Trends of Indonesia Oral Anti-Diabetic Drug Industry
Sulfonylureas Segment Occupied the Highest Market Share in the Indonesia Oral Anti-Diabetic Drugs Market in the current year.
Regarding revenue, the Sulfonylureas segment is anticipated to lead the Indonesia Oral Anti-Diabetic Drugs Market and post a CAGR of over 1% during the forecast year. Among the several Oral anti-diabetes drugs available, sulfonylureas (SUs) constitute one of the key pharmacotherapeutic agents in managing T2DM.
In Indonesia, healthcare professionals provide diabetes education programs. A lack of skilled healthcare professionals (HCPs) to teach people with diabetes is caused by the limited availability of certified diabetic educators in Indonesia. Little evidence is available about how people with diabetes learn about their condition after acquiring diabetes-related information formally or informally through formal educational programs in Indonesia. Sulfonylureas, combined with metformin, are one of the oral AHAs often recommended in low- and middle-income (LMIC) nations of Asia and Africa.
This family of medications lowers hyperglycemia and glycated hemoglobin (HbA1c) levels in T2DM patients by increasing insulin release from Beta-cells. According to the hierarchy of development, the SUs are divided into first- and second-generation SUs, and according to the length of time they are active, they are categorized as short, intermediate, and long-acting SUs. Clinical trials have indicated that fixed-dose combinations of SUs plus metformin or other glucose-lowering drugs are safe and effective. The National List of Necessary Medicines (NLEM) issued by numerous nations in the African, Middle Eastern and North African, and Southeast Asian area includes the SUs as one of the necessary AHAs.
The increasing Diabetes Population in the Indonesia is driving the market.
People with diabetes in Indonesia rank sixth in the world, along with China, India, the United States, Brazil, and Mexico, with an estimated number of people with diabetes of 12 million. It is expected to increase to 17 million people in 2045. Indonesia is the eighth most diabetic country in the world. The national government's insurance program mostly covers people's health costs in Indonesia. Medical necessities, including consultations, hospital stays, insulin, and needles, are covered by government insurance when obtained through certain clinics, hospitals, or licensed pharmacies. However, a misconception developed because of a lack of awareness and information about type 1 diabetes, leading to restrictions on insulin access.
The quantity of insulin covered by government insurance was restricted. For instance, a kid with type 1 diabetes who needed eight insulin pens per month was only provided five, forcing the parents to pay for the other three pens independently. They were not allowed to give their child medication if they did not have the money. In Indonesia, healthcare professionals provide diabetes education programs.
A lack of skilled healthcare professionals (HCPs) to teach people with diabetes is caused by the limited availability of certified diabetic educators in Indonesia. Little evidence is available about how people with diabetes learn about their condition after acquiring diabetes-related information formally or informally through formal educational programs in Indonesia. The absence of comprehensive health insurance in Indonesia makes creating a responsive healthcare system more difficult. The government wants everyone to have access to health care.
The main public health insurance program is Askeskin/Jamkesmas, a national health insurance scheme for the underprivileged. Askes provides health insurance to retired military members and governmental servants. Jamsostek covers the formal sector. Meanwhile, just around 3% of people have private health insurance.
